Industry
Biogen Inc. (NASDAQ:BIIB) Undervalued? Fundamentals Hard To Beat?
Biogen Inc. (NASDAQ:BIIB) Relative Strength Index (RSI) is 69.96, with weekly volatility at 3.70% and ATR at 19.45. The BIIB stock’s 52-week price range has
Biogen Inc. (NASDAQ:BIIB) Relative Strength Index (RSI) is 69.96, with weekly volatility at 3.70% and ATR at 19.45. The BIIB stock’s 52-week price range has
Biogen Inc. (NASDAQ:BIIB) shares fell to a low of $395.14 before closing at $406.14. Intraday shares traded counted 2.1 million, which was -22.66% lower than
Alzheimer’s disease slowly destroys the brain’s memory and cognitive skills. Aducanumab will be the only drug effective in treating the disease and not relieving its
Biogen Inc. (NASDAQ:BIIB) stock’s Relative Strength Index (RSI) is 63.15, with weekly volatility at 3.20% and ATR at 7.35. The BIIB stock’s 52-week price range
Biogen Inc. (NASDAQ:BIIB) stock’s Relative Strength Index (RSI) is 44.52, with weekly volatility at 2.22% and ATR at 6.51. The BIIB stock’s 52-week price range
Biogen Inc. (NASDAQ:BIIB) previous close was $278.86 while the outstanding shares total 151.90M. The firm has a beta of 0.42, a 12-month trailing P/E ratio
Discover high-quality information at your convenience with ‘State Reviewer.’ Our news portal offers valuable insights for free, available in accessible locations such as metro stations, busy intersections, cafes, and business centers. Wherever your day takes you, ‘State Reviewer’ ensures you’re never out of touch with the latest news and updates.
All rights reserved © 2024, Powered by Smart TechOne